DRIO DarioHealth Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1533998 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.9%
TTM net income YoY19.5%
TTM EPS YoY-67.7%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin57.9%
Operating margin-142.7%
Net margin-159.9%
FCF margin-111.0%
EBITDA margin-141.7%
Returns
ROE-46.6%
ROA-29.6%
ROIC (approx.)-32.4%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets36.6%
Debt / equity0.44x
Current ratio4.20x
Interest coverage-6.81x
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-9.1%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $22.36M | $27.04M | $20.35M | $27.66M | $20.51M |
| Cost of revenue | $9.69M | $13.77M | $14.37M | $18.00M | $16.55M |
| Gross profit | $12.66M | $13.27M | $5.98M | $9.65M | $3.96M |
| R&D expense | $13.79M | $24.18M | $20.25M | $19.65M | $17.22M |
| SG&A expense | $15.19M | $20.48M | $18.14M | $16.49M | $23.53M |
| Operating income | -$36.66M | -$57.74M | -$56.19M | -$56.81M | -$76.49M |
| Interest expense | $3.02M | — | — | $1.88M | — |
| Pretax income | -$41.61M | -$44.60M | -$59.36M | -$62.19M | -$76.73M |
| Income tax | $105,000 | -$1.85M | $64,000 | $4,000 | $32,000 |
| Net income | -$41.71M | -$42.75M | -$59.43M | -$62.19M | -$76.76M |
| EBITDA | -$36.35M | -$56.42M | -$55.72M | -$56.45M | -$76.21M |
| EPS (basic) | 10.12 | 12.27 | 1.93 | 2.54 | 4.07 |
| EPS (diluted) | 10.12 | 12.27 | 1.93 | 2.54 | 4.07 |
| Weighted avg. shares (diluted) | 3.98M | 2.45M | 28.37M | 23.64M | 16.59M |
| Balance sheet | |||||
| Cash & equivalents | $21.80M | $27.76M | $36.80M | $49.47M | $35.95M |
| Short-term investments | $4.21M | — | — | — | — |
| Inventory | $4.32M | $4.75M | $5.06M | $7.96M | $6.23M |
| Current assets | $35.07M | $40.53M | $47.33M | $65.52M | $45.60M |
| PP&E, net | $549,000 | $709,000 | $899,000 | $788,000 | $702,000 |
| Goodwill | $57.43M | $57.43M | $41.64M | $41.64M | $41.64M |
| Intangibles | $15.93M | $18.76M | $5.40M | $9.92M | $12.46M |
| Total assets | $110.08M | $118.88M | $96.39M | $119.19M | $100.77M |
| Current liabilities | $9.32M | $16.64M | $12.49M | $19.35M | $14.38M |
| Short-term debt | — | $5.45M | $3.95M | $8.82M | $0 |
| Long-term debt | $30.75M | $23.47M | $24.59M | $18.11M | $0 |
| Total debt | $30.75M | $28.92M | $28.55M | $26.93M | $0 |
| Total liabilities | $42.15M | $46.87M | $38.24M | $39.19M | $15.22M |
| Shareholders' equity | $67.92M | $72.02M | $58.14M | $80.00M | $85.55M |
| Net debt | $8.94M | $1.16M | -$8.25M | -$22.54M | -$35.95M |
| Shares outstanding | 6.91M | 1.92M | 27.19M | 25.72M | 16.57M |
| Cash flow statement | |||||
| Operating cash flow | -$25.94M | -$38.56M | -$30.38M | -$47.84M | -$50.41M |
| Capital expenditure | $142,000 | $138,000 | $584,000 | $442,000 | $261,000 |
| Free cash flow | -$26.08M | -$38.70M | -$30.96M | -$48.29M | -$50.67M |
| Investing cash flow | -$4.34M | -$8.93M | -$547,000 | -$573,000 | -$8.13M |
| Financing cash flow | $24.31M | $38.53M | $18.25M | $61.94M | $65.77M |
| Depreciation & amortization | $307,000 | $1.33M | $473,000 | $356,000 | $282,000 |
| Stock-based compensation | $9.37M | $46,000 | $19.70M | $16.98M | $24.97M |
| Share buybacks | — | — | — | $134,000 | — |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.